Stephan Schleim- Theory and History of Psychology, Heymans Institute for Psychological Research, Faculty of Behavioral and Social Sciences, University of Groningen, Groningen, Netherlands
Introduction
Langlitz and colleagues wrote about clinically used psychedelic drugs and the possibility of a “moral psychopharmacology” earlier in this journal (1). They emphasized the context-dependency of the effects of these substances (e.g., ayahuasca, psilocybin) and the importance of understanding their impact on social and moral cognition, particularly now that there is more research on their possible clinical applications (e.g., to facilitate psychotherapy). In this opinion article, I want to, first, reflect on the context-dependency from the perspective of recent research on placebo effects, and, second, clarify different meanings of “moral psychopharmacology”. The latter will be placed in the context of a broader conceived view on drug instrumentalization (2–4) and different values associated with it (5–7). In the conclusion, I will briefly distinguish aspects primarily relevant to theoretical, research-oriented, or applied perspectives, respectively, to inform further theoretical, empirical, and ethical discussion of these topics.
Context-Dependency of Drugs
In line with the proverbial emphasis on the importance of “set and setting” for the consumption of psychedelic substances, Langlitz and colleagues discuss research reporting different experiences associated with the use of hallucinogens in different social contexts (“settings”). In what has become a classic study, Wallace indeed found that the experiential content of dreams and hallucinations depends on one's cultural and social background (8). Similarly, in another classic study, Bourque and Back found that lower-educed people with lower incomes in the USA described transcendental experiences more in religious terms, whereas higher-educated people with higher incomes used more aesthetic concepts (9). More recently, a comparison between schizophrenia patients from more or less religious regions in East and West Germany showed that the former reported less religious content in their hallucinations than the latter (10).
Langlitz and colleagues, like other researchers, subsequently distinguish pharmacological and extra-pharmacological effects, particularly in research on psychedelics (1, 11–13). But actually already a classic social-psychological study with adrenaline investigated “cognitive, social, and physiological determinants of emotional state” (14). Subjects either received correct, incorrect, or no information about the expected physiological responses (such as increased heart rate, feeling warmth) of an adrenaline injection presented to them as a vitamin shot.1 In a following funny social interaction, they reported significantly more euphoria and were more active without the correct information, that is, when they had no rational explanation of the physiological symptoms. A similar outcome was reported for an anger-inducing social interaction. Thus the outcome variable (here: emotional state and behavior) depends on an interaction of the expectation, social setting, and pharmacologically induced physiological state of the subjects.2
Research on the placebo effect provides more examples. In recent years, scientists focused on explaining its psychobiological mechanisms and clinical potential (15, 16). Some actually criticize the notion of placebo as an “inert substance” as inconsistent, for something inert can conceptually not have any effects. They thus propose the alternative notions of a “context effect” or “meaning response” (15, 17–20), where the former expression emphasizes social context and the latter term individual beliefs or expectations, thus precisely what Langlitz and colleagues refer to when speaking of extra-pharmacological effects. Strikingly, research has shown that the context effect or meaning response can consist in activating the same physiological pathways as drugs used to alleviate a certain medical problem, such as the activation of endogenous opioids and dopamine for pain treatment (15).
Langlitz and colleagues refer to different epistemic cultures in the natural sciences on the one hand and the humanities and social sciences on the other, with common dichotomies of nature/culture or matter/mind. Consistent with a theoretical framework presented by Greenberg and Bailey, I take the stance which Turkheimer coined “weak biologism” (21, 22). This means that there is no strict dichotomy between the biological and non-biological, because in some sense all of our perceptions, thoughts, behaviors, and the like are biological—if only in that they have a biological basis, because we are embodied beings (23–27). These bodies were shaped through an evolutionary history and particularly their nervous systems enable a wide range of psychological and cultural possibilities, which in turn also influence biological structure and function (i.e. neuroplasticity). For example, certain brain (and other physiological) structures allow us to acquire language; without them, we could not understand and express it. But it's the psychosocial context determining whether one's primary language will be, say, Chinese, English, or Spanish.
Applied to Langlitz's and colleagues' thoughts, this means that there is also no strict dichotomy between pharmacological and extra-pharmacological factors: Just as anthropological research-at least implicitly—always includes (and presupposes) certain bodies and brains, pharmacological research always includes (and presupposes) a psychosocial context, often a clinical setting in which a substance is administered. In other words, our cognitive and emotional processes are not only (physically) embodied, but also (psychosocially) embedded (23–27). Kaptchuk already described how, from an anthropological perspective, common procedures even in Western medical systems could be described as a “ritual”, thus a particular psychosocial context affecting the treatment effects (28).3 We may tend to overlook this, because we take that context for granted. It then also makes sense that research on psychedelic substances in particular prompts scholars to focus more on context effects, as these substances (like ayahuasca, religiously used in South America and consisting of N,N-Dimethyltryptamine [DMT] and a monoamine oxidase inhibitor [MAOI]) often originate in different cultures with particular practices of consumption or “rituals” (13, 29–31).
The upshot of my proposal is that there is no intrinsic contradiction between the tasks of anthropologists, psychologists, or pharmacologists: The latter often won't investigate the psychosocial context (as an independent variable, that is) simply for the reason that the respective drug is supposed to be taken within a particular context. Thus, in principle, if pharmacologists became interested in cultural differences or specific effects of psychosocial contexts, they could simply include them in their experimental designs. Whether the resulting discipline deserved a new denomination like “transcultural pharmacology” (cf. transcultural psychiatry) or “pharmanthropology” lies in the eye of the beholder. Strictly distinguishing pharmacological and extra-pharmacological effects, by contrast, carries the risk of reintroducing unnecessary dichotomies; unnecessary, because, as we have seen, the former never comes without the latter.
One could speculate, though, whether the biological (or pharmacological) domain has some primacy in the sense that without the enabling physiological structures and functions there would simply be no anthropological, social, or psychological domain. Experimentally this could be exemplified—within ethical boundaries—by increasing pharmacological doses and thus eventually overriding or at least minimizing effects of psychosocial context (32). Anesthesia is a clear example, as it transiently disables certain psychosocially necessary functions—and thus psychosocial processes. In the words of a patient participating in one of Delgado's early brain stimulation experiments: “I guess, Doctor, that your electricity is stronger than my will” (33, 34). But this does not make the case for “strong biologism”, on Turkheimer's account, which would mean that psychosocial functions could be explained completely or at least for a large part in biological terms. Similar to how Steven Hyman, former director of the US National Institute of Mental Health, recently characterized psychiatric disorders, one could say: The psychosocial processes of pharmaceutical drugs are grounded, but not exhausted in biology (35).
Moral Psychopharmacology and Values
Langlitz and colleagues continue to discuss a possible “moral psychopharmacology”. Indeed, after neuroscientists began to investigate moral decision-making (36–40), pharmacologists also addressed that domain (41, 42) and ethicists speculated about “moral enhancement”, the possibility of using drugs to improve people's moral capacities (43, 44). The ecological validity of the moral dilemmas often used in such studies and their (alleged) social implications have subsequently been discussed critically (45–48). Here it helps, in my view, to distinguish different meanings of “moral” on the one hand and individual or collective perspectives on morality on the other.
In a loose sense of “moral”, as pertaining to moral implications, the term is more or less equivalent with “social”. Then, according to Langlitz's and colleagues' call for more awareness for the potential effects of psychedelic drugs in the social domain, one could say that this is valid for psychoactive drugs in general. Unless one imagines the life of a hermit, it would be difficult to think of a psychopharmacological application that could not, in principle, have any social implications (e.g., think of the possibility of substances to interfere with people's capacity to control vehicles or machines, which could in turn harm themselves or others and thus become socially relevant). Here it would be important to distinguish transient and permanent effects (with the latter possibly altering personality). It would still make sense, as Langlitz and colleagues suggest, to investigate the potential effects of psychedelic (and other psychoactive) drugs on social cognition. But this should be distinguished, in my view, from a “moral psychopharmacology” in a narrower sense: that is, one that specifically aims at improving subjects' moral cognition. To my knowledge, pharmacological experiments so far used the previously mentioned moral decision-making paradigms, but did not explicitly try to enhance moral competence as operationalized by, for example, Lind's Moral Judgment Test (49, 50). The general problem remains that there is no single accepted standard of what a “good” moral decision is; this would always presuppose a particular moral theory or stance, of which there are many different ones competing in moral philosophy.
Before improving moral capacities, there thus has to be a value judgment on what kind of moral capacity is deemed desirable. Langlitz and colleagues, just like Evers before, particularly address the possibility of increasing empathy on the neurobiological level (1, 51–53). But this raises the question whether more empathy is always morally good. It could make people prone to overrate the preferences of others at the cost of their own wellbeing (54). What if egoists or “successful psychopaths” who hardly care for the interests of others as a value in itself disagree to become “morally enhanced” in this sense? This also raises the question who is to decide: Without informed consent of the subjects themselves, some would consider “moral psychophamarcology” as coercive or even totalitarian. And based on informed consent there would probably always be individuals deciding against such an intervention, simply because people have different values and think differently about the instrumental use of substances. This dilemma was actually already debated by psychiatrist Klerman and bioethicist Veatch half a century ago (5–7). Different value systems and different understandings of human nature shape people's views on drug use differently. The category not addressed by Langlitz and colleagues, but central in medical ethics, is that of autonomy. People should primarily decide for themselves, but also considering their own psychosocial context (55). From this perspective, “moral psychopharmacology” could be understood as one example of instrumental substance use more broadly conceived (2–4). People might use drugs to become more moral—if and only if they themselves desire so.
Conclusion
On the theoretical level, psychosocial effects (contexts and beliefs/expectations) on how a drug (psychedelic or not) work are neither surprising nor an insurmountable problem. When humans are conceived as a psychobiological unity in a social environment, “weak biologism” or the idea of the psychosocial domain being grounded in biology predicts precisely that: that psychological processes are embodied and thus also reflected in a subject's physiological state (23–27). An example from research on the placebo effect has shown that the physiological pathway can actually be the same as the one activated by a drug to treat a particular medical problem (15). This also exemplifies the clinical relevance of understanding the effects of context or beliefs/expectations on drugs. Generally speaking, there is no reason why anthropologists should disregard pharmacology or why pharmacologists should neglect psychosocial context—if that becomes salient for their research questions. Whether this justifies the establishment of a “transcultural pharmacology” or “pharmanthropology” as an independent sub-discipline may be a matter of taste. But from the point of view presented here, the context-dependency of psychedelic drug effects rather means opportunities, not problems for anthropology and pharmacology.
Author Contributions
The author confirms being the sole contributor of this work and has approved it for publication.
Funding
This publication has been supported by the History of Neuroethics grant by the Dutch Research Foundation (NWO), Grant Number: 451-15-042.
Conflict of Interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
I would like to thank Boris B. Quednow at the University Clinics Zurich and my colleagues at the Theory and History of Psychology Department in Groningen for helpful comments on an earlier version of this manuscript.
Footnotes
1. ^It goes without saying that, from a present perspective, this procedure is ethically dubious. Yet the study is so informative that it already received more than 10,000 Google Scholar citations and is still cited frequently.
2. ^It should be noted, though, that their placebo control was descriptively, but not statistically significantly between the conditions with and without the correct information. This should be seen in the context of the small sample sizes per group (N = 25 or 26).
3. ^A peer reviewer made the interesting remark that purported effects of microdosing of psychedelic drugs in the newly arising microdosing subculture has topical relevance and may be interesting in the context of discussing placebo effects and research Kaptchuck's. Further pursuing this link goes beyond the scope of this short opinion article.
References
1. Langlitz N, Dyck E, Scheidegger M, Repantis D. Moral psychopharmacology needs moral inquiry: the case of psychedelics. Front Psychiat. (2021) 12. doi: 10.3389/fpsyt.2021.680064
2. Müller CP, Schumann G. Drugs as instruments: a new framework for non-addictive psychoactive drug use. Behav Brain Sci. (2011) 34:293–310. doi: 10.1017/S0140525X11000057
3. Schleim S. Neuroenhancement as instrumental drug use: Putting the debate in a different frame. Front Psychiat. (2020) 11. doi: 10.3389/fpsyt.2020.567497
4. Müller CP. Drug instrumentalization. Behav Brain Res. (2020) 390:112672. doi: 10.1016/j.bbr.2020.112672
5. Veatch RM. Value foundations for drug use. J Drug Issues. (1977) 7:253–62. doi: 10.1177/002204267700700305
6. Klerman GL. Drugs and social values. Int J Addict. (1970) 5:313–9. doi: 10.3109/10826087009056998
7. Klerman GL. Psychotropic hedonism vs. pharmacological Calvinism. Hast Center Report. (1972) 4:1–3. doi: 10.2307/3561398
8. Wallace AFC. Cultural determinants of response to hallucinatory experience. AMA Arch General Psychiat. (1959) 1:58–69. doi: 10.1001/archpsyc.1959.03590010074009
9. Bourque LB, Back KW. Language, society and subjective experience. Sociometry. (1971) 34:1–21. doi: 10.2307/2786348
10. Pfaff M, Quednow BB, Brüne M, Juckel G. Schizophrenia and religiousness–a comparative study at the time of the two German states. Psychiatr Prax. (2008) 35:240–6. doi: 10.1055/s-2007-986349
11. Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. (2018) 32:725–31. doi: 10.1177/0269881118754710
12. Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. (2016) 30:1259–67. doi: 10.1177/0269881116677852
13. Hartogsohn I. Set and setting in the santo daime. Front Pharmacol. (2021) 12. doi: 10.3389/fphar.2021.651037
14. Schachter S, Singer J. Cognitive, social, and physiological determinants of emotional state. Psychol Rev. (1962) 69:379–99. doi: 10.1037/h0046234
15. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. (2010) 375:686–95. doi: 10.1016/S0140-6736(09)61706-2
16. Kirsch I. Placebo effect in the treatment of depression and anxiety. Front Psychiat. (2019) 10. doi: 10.3389/fpsyt.2019.00407
17. Moerman DE. “Placebo” versus “meaning”: The case for a change in our use of language. (2003) 6:1–5. doi: 10.1037/1522-3736.6.1.67c
18. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. Ann Internal Med. (2002) 136:471–6. doi: 10.7326/0003-4819-136-6-200203190-00011
19. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence of context effects on health outcomes: a systematic review. Lancet. (2001) 357:757–62. doi: 10.1016/S0140-6736(00)04169-6
20. Di Blasi Z, Kleijnen J. Context effects: powerful therapies or methodological bias? Eval Health Prof. (2003) 26:166–79. doi: 10.1177/0163278703026002003
21. Greenberg AS, Bailey JM. The irrelevance of the medical model of mental illness to law and ethics. Int J Law Psychiat. (1994) 17:153–73. doi: 10.1016/0160-2527(94)90023-X
22. Turkheimer E. Heritability and biological explanation. Psychol Rev. (1998) 105:782–91. doi: 10.1037/0033-295X.105.4.782-791
23. Schleim S. To Overcome psychiatric patients' mind–brain dualism, reifying the mind won't help. Front Psychiat. (2020) 11. doi: 10.3389/fpsyt.2020.00605
24. Varela FJ, Thompson E, Rosch E. The Embodied Mind, Revised Edition: Cognitive Science and Human Experience. MIT press. (2017). doi: 10.7551/mitpress/9780262529365.001.0001
25. Schleim S. Gehirn, Psyche Und Gesellschaft: Schlaglichter Aus Den Wissenschaften Vom Menschen. Berlin: Springer. (2021). doi: 10.1007/978-3-662-62229-2
26. Kotchoubey B, Tretter F, Braun HA, Buchheim T, Draguhn A, Fuchs T, et al. Methodological problems on the way to integrative human neuroscience. Front Integrat Neurosci. (2016) 10. doi: 10.3389/fnint.2016.00041
27. Menary R. Introduction to the special issue on 4E cognition. Phenomenol Cogn Sci. (2010) 9:459–63. doi: 10.1007/s11097-010-9187-6
28. Kaptchuk TJ. Placebo studies and ritual theory: a comparative analysis of Navajo, acupuncture and biomedical healing. Philosoph Transact Royal Soc B: Biol Sci. (2011) 366:1849–58. doi: 10.1098/rstb.2010.0385
29. Dobkin de Rios M. Ayahuasca–the healing vine. Int J Soc Psychiat. (1971) 17:256–69. doi: 10.1177/002076407101700402
30. McKenna DJ. The healing vine: ayahuasca as medicine in the 21st century. In: Winkelman MJ, Roberts TB, editors. Psychedelic medicine: New evidence for hallucinogenic substances as treatments. Praeger Publishers/Greenwood Publishing Group. (2007). p. 21–44.
31. Dupuis D. The socialization of hallucinations: cultural priors, social interactions, and contextual factors in the use of psychedelics. Transcult Psychiatry. (2021) 12:13634615211036388. doi: 10.1177/13634615211036388
32. Quednow BB. Tyrannische Neurobiologie und unterdrückte Kultur des psychotropen Erlebens. Zeitschrift für Kulturwissenschaften. (2010) 2:79–84.
33. Schleim S. Neurorights in History: A Contemporary Review of José M. R. Delgado's “Physical Control of the Mind” (1969) and Elliot S. Valenstein's “Brain Control” (1973). Front Human Neurosci. (2021) 15. doi: 10.3389/fnhum.2021.703308
34. Delgado JM. Physical Control of the Mind: Toward a Psychocivilized Society. Harper & Row. (1971).
35. Hyman SE. Psychiatric disorders: Grounded in human biology but not natural kinds. Perspect Biol Med. (2021) 64:6–28. doi: 10.1353/pbm.2021.0002
36. Greene JD, Nystrom LE, Engell AD, Darley JM, Cohen JD. The neural bases of cognitive conflict and control in moral judgment. Neuron. (2004) 44:389–400. doi: 10.1016/j.neuron.2004.09.027
37. Greene JD, Sommerville RB, Nystrom LE, Darley JM, Cohen JD. An fMRI investigation of emotional engagement in moral judgment. Science. (2001) 293:2105–8. doi: 10.1126/science.1062872
38. Moll J, de Oliveira-Souza R. Moral judgments, emotions and the utilitarian brain. Trends Cogn Sci. (2007) 11:319–21. doi: 10.1016/j.tics.2007.06.001
39. Moll J, Eslinger PJ, de Oliveira-Souza R. Frontopolar and anterior temporal cortex activation in a moral judgment task - Preliminary functional MRI results in normal subjects. Arquivos De Neuro-Psiquiatria. (2001) 59:657–64. doi: 10.1590/S0004-282X2001000500001
40. Schleim S, Spranger TM, Erk S, Walter H. From moral to legal judgment: the influence of normative context in lawyers and other academics. Soc Cogn Affect Neur. (2011) 6:48–57. doi: 10.1093/scan/nsq010
41. Crockett MJ, Clark L, Tabibnia G, Lieberman MD, Robbins TW. Serotonin modulates behavioral reactions to unfairness. Science. (2008) 320:1739. doi: 10.1126/science.1155577
42. Forstmann M, Yudkin DA, Prosser A, M B, Heller SM, Crockett MJ. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proc Nat Acad Sci. (2020) 117:2338–46. doi: 10.1073/pnas.1918477117
43. Douglas T. Moral enhancement. J Appl Philos. (2008) 25:228–45. doi: 10.1111/j.1468-5930.2008.00412.x
44. Dubljević V, Racine E. Moral enhancement meets normative and empirical reality: assessing the practical feasibility of moral enhancement neurotechnologies. Bioethics. (2017) 31:338–48. doi: 10.1111/bioe.12355
45. Schleim S. Moral Physiology, Its Limitations and Philosophical Implications. Jahrbuch für Wissenschaft und Ethik. (2008) 13:51–80. doi: 10.1515/9783110196832.1.51
46. Schleim S. The Half-Life of the Moral Dilemma Task: A Case Study in Experimental (Neuro-) Philosophy. In: Clausen J, Levy N, editors. Handbook of Neuroethics. Dordrecht: Springer; (2015). p. 185–99. doi: 10.1007/978-94-007-4707-4_164
47. Waldmann MR, Nagel J, Wiegmann A. Moral Judgment. In: Holyoak KJ, Morrison RG, editors. The Oxford Handbook of Thinking and Reasoning: Oxford University Press. (2012). p. 364–89. doi: 10.1093/oxfordhb/9780199734689.013.0019
48. Kahane G, Shackel N. Methodological issues in the neuroscience of moral judgement. Mind Lang. (2010) 25:561–82. doi: 10.1111/j.1468-0017.2010.01401.x
49. Mouratidou K, Chatzopoulos D, Karamavrou S. Validity study of the moral judgment test in physical education: development and preliminary validation. Percept Mot Skills. (2008) 106:51–62. doi: 10.2466/pms.106.1.51-62
50. Lind G. The moral judgment test: comments on Villegas de Posada's critique. Psychol Rep. (2006) 98:580–4. doi: 10.2466/pr0.98.2.580-584
51. Schleim S. Should we be Epigenetically Proactive? In: Metzinger TK, Windt JM, editors. Open MIND. Frankfurt am Main: MIND Group. (2015). p. 1–15.
52. Evers K. Can we be epigenetically proactive? In: Metzinger TK, Windt JM, editors Open MIND Frankfurt am Main: MIND Group. (2015).
53. Schleim S. When empathy became a brain function: a neurophilosophical case study. Philosophy, Theol Sci. (2015) 2:41–62. doi: 10.1628/219597715X14268452692942
54. Schleim S. Whose well-being? Common conceptions and misconceptions in the enhancement debate. Front Syst Neurosci. (2014) 8. doi: 10.3389/fnsys.2014.00148
Keywords: psychedelic drugs, psychedelics, placebo, context-dependency, embodiment, mind-body problem, 4E cognition
Citation: Schleim S (2022) Grounded in Biology: Why the Context-Dependency of Psychedelic Drug Effects Means Opportunities, Not Problems for Anthropology and Pharmacology. Front. Psychiatry 13:906487. doi: 10.3389/fpsyt.2022.906487
Received: 28 March 2022; Accepted: 19 April 2022;
Published: 11 May 2022.
Edited by:
Marijn Lijffijt, Baylor College of Medicine, United StatesReviewed by:
Andrew Penn, University of California, San Francisco, United StatesCopyright © 2022 Schleim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stephan Schleim, cy5zY2hsZWltJiN4MDAwNDA7cnVnLm5s